Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia (Q55966607)

1

0 references

Stephan Harbarth

8

object named as

Stephan Harbarth

0 references

author name string

Daiana Stolz

2

0 references

Christian Müller

4

0 references

David Miedinger

5

0 references

Peter R. Huber

6

0 references

Werner Zimmerli

7

0 references

Michael Tamm

9

0 references

Beat Müller

American Journal of Respiratory and Critical Care Medicine

10

0 references

language of work or name

English

0 references

publication date

July 2006

0 references

published in

0 references

volume

174

0 references

issue

1

0 references

page(s)

84-93

0 references

cites work

Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC

Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC

Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC

Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC

Pneumonia in the very old

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC

Quality of care, process, and outcomes in elderly patients with pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC

What is optimal antimicrobial therapy for bacteremic pneumococcal pneumonia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC

Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC

Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC

Short-course treatment of community-acquired pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC

Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC

Diagnosing pneumonia by physical examination: relevant or relic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC

Procalcitonin and ventilator-associated pneumonia: yet another breath of fresh air.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC

Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC

Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC

In vitro and in vivo calcitonin I gene expression in parenchymal cells: a novel product of human adipose tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC

Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC

Early immunoneutralization of calcitonin precursors attenuates the adverse physiologic response to sepsis in pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC

Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC

The revised CONSORT statement for reporting randomized trials: explanation and elaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC

A prediction rule to identify low-risk patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC

The future diagnostic role of procalcitonin levels: the need for improved sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC

Clinical practice. Management of community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC

Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC

Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC

Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC

Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC

Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatme

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC

Toward a consensus definition for COPD exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC

Community-acquired pneumonia: causes of treatment failure in patients enrolled in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC

High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC

Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC

Preventing the risk of emergence of bacterial resistance associated with antibiotic therapy: what role for pharmacokinetic and pharmacodynamic data?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC

Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC

Trends in antimicrobial drug prescribing among office-based physicians in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC

Outpatient antibiotic use in Europe and association with resistance: a cross-national database study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC

How antibiotics can make us sick: the less obvious adverse effects of antimicrobial chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC

Guidelines for the Treatment of Community-acquired Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1922OC